ARTICLE | Clinical News
Bertilimumab: Phase II started
August 18, 2014 7:00 AM UTC
Immune Pharmaceuticals began patient screening in an open-label Phase II trial to evaluate 2 doses of 10 mg/kg IV bertilimumab given 14 days apart in 10-15 patients with moderate to severe bullous pemphigoid. Patients will also receive oral prednisone at an initial dose of 30 mg daily, which will be tapered down based on patient response. ...